EBITDA was recorded at Rs. 2.7 billion in Q1 FY09 as against Rs 2.9 billion in Q1 FY08 while Profit After Tax witnessed a decline from Rs 1.8 billion Q1 of the fiscal year 2007-08 to Rs 1.3 billion in Q1 of the fiscal year 2008-09, according to a press release here. Revenues from Global Generics business increased by 25 per cent to Rs 10.3 billion in the first quarter this year from Rs 8.3 billion in first quarter last year.
Revenues from Pharmaceutical Services&Active Ingredients (PSAI) increased by 27 per cent to Rs 4.6 billion in Q1 FY09 as against Rs 3.6 billion in Q1 FY08.
During the quarter, the company launched 26 new generic products, filed 20 new generic product registrations and 11 DMFs globally.